BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Roflumilast (Zoryve foam) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Roflumilast (Zoryve foam)\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07683806-11037@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Roflumilast (Zoryve foam): Phase 3 readout est. (NCT07683806)
DESCRIPTION:Roflumilast (Zoryve foam)\, phase 3\, Seborrheic Dermatitis.\nS
 tudy: Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants W
 ith Seborrheic Dermatitis\nEstimated primary completion: 30 June 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/roflumilast-zoryve-foam#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0768
 3806
URL:https://assetmemo.bio/drug/roflumilast-zoryve-foam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07639840-11037@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Roflumilast (Zoryve foam): Phase 2 readout est. (NCT07639840)
DESCRIPTION:Roflumilast (Zoryve foam)\, phase 2.\nStudy: An Open-label\, Si
 ngle Center Study Evaluating the Safety and Efficacy of Roflumilast Foam 0
 .3% in Subjects With Cutaneous Adverse Events Due to Checkpoint Inhibitors
 \nEstimated primary completion: 1 August 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/roflumilast-zoryve-foam#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07639840
URL:https://assetmemo.bio/drug/roflumilast-zoryve-foam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07689188-11037@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20280310
DTEND;VALUE=DATE:20280311
SUMMARY:Roflumilast (Zoryve foam): Phase 2 readout est. (NCT07689188)
DESCRIPTION:Roflumilast (Zoryve foam)\, phase 2.\nStudy: Safety and Efficac
 y of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradeni
 tis Suppurativa\nEstimated primary completion: 10 March 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/roflumilast-zoryve-foam#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07689188
URL:https://assetmemo.bio/drug/roflumilast-zoryve-foam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07263230-11037@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Roflumilast (Zoryve foam): Phase 2 readout est. (NCT07263230)
DESCRIPTION:Roflumilast (Zoryve foam)\, phase 2.\nStudy: The Safety and Eff
 icacy of Roflumilast Foam in HS\nEstimated primary completion: August 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/roflumilast-zoryve-
 foam#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07263230
URL:https://assetmemo.bio/drug/roflumilast-zoryve-foam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
